Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.

VolitionRx Limited announces data from a pilot study into the utility of VolitionRx’s NuQ® tests to diagnose prostate cancer. 

The results from the trial show that VolitionRx NuQ® assays were able to detect approximately 80 per cent of prostate cancer cases. Significantly, the trial showed that not only does the test have a high detection rate for prostate cancer, but it can differentiate between colorectal and prostate cancer. It does this by detecting the levels of epigenetically altered circulating nucleosomes in each sample, the structure of which Volition has found to be different in the two different types of cancer. For example, levels of circulating nucleosomes containing H3K9(Me)3 were elevated in colorectal cancer, but supressed in prostate cancer.  This indicates that NuQ® ELISA tests could be used to detect both prostate and colorectal cancers. 

Dr. Jake Micallef, Chief Scientific Officer at VolitionRx, will present a poster at The International Society of Oncology and Biomarkers Congress (ISOBM) in Barcelona, sharing results of the latest study into the effectiveness of NuQ® assays as an initial screening tool in detecting colorectal and now prostate cancer.  The poster abstract and a PDF of the poster is available on the VolitionRx website at: http://volitionrx.com/technologies-abstracts-papers-posters.html. 

“This is a very exciting outcome for us as we continue the development of our NuQ tests,” says Dr. Jake Micallef. “To have proof that with the right panel combination, NuQ tests can distinguish between different types of cancer as well as healthy samples, is just what we’ve been working towards. Detection of two major cancers with a blood test is a major milestone and a sound basis on which to investigate further cancers for panels of NuQ tests that detect and distinguish cancer diseases.”

NuQ® assays identify and measure circulating nucleosomes structures for the presence of epigenetic cancer signals within the blood. Results from another recent trial conducted demonstrated that the NuQ® assays were able to also detect more than 85 per cent of colorectal cancer cases with greater than 85 per cent specificity. The earlier study took samples from both healthy subjects and subjects recently diagnosed with colorectal cancer.      

Volition is carrying out several clinical trials on the effectiveness of the NuQ® assays as a cancer diagnostic tool: 

• A 4,800 patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. 

• A 2,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany.

• A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.
Thursday, April 24, 2014
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!